HOME >> BIOLOGY >> NEWS
Ethnicity and cancer susceptibility

(London, September 10) Researchers from the UCL Branch of the global Ludwig Institute for Cancer Research (LICR) have uncovered how a genetic variation present in ethnic groups from around the equator may influence cancer susceptibility. The findings published in Nature Genetics have implications for pharmacogenetics, the study of how inherited variations may affect drug metabolism and response, and present a target for future 'designer' cancer therapies.

The p53 tumor-suppressor protein removes damaged cells by a programmed cell death (apoptosis). When the p53 gene is mutated - as it is in approximately half of all human cancers - damaged cells do not die, but rather continue to grow and divide and eventually form a tumor. The two most common polymorphic forms of p53 are p53Pro72 and p53Arg72 and the distribution varies in different ethnic groups. The two forms differ by just one amino acid in the protein sequence. Several years ago, the LICR team discovered that the ability of p53 to control apoptosis is regulated by the ASPP family of proteins.

In this study, the investigators showed that the ASPP family preferentially regulates the p53Pro72 over p53Arg72 form. These results suggest that ASPP protein levels determine cancer susceptibility in people with the p53Pro72 form, the prevalence of which is linked closely to latitude.

According to Professor Xin Lu, the senior author of the study and Director of the LICR Branch, the occurrence of the p53Pro72 form is highest in ethnic populations from around the equator. "It's really interesting to speculate whether the increased exposure to DNA-damaging ultraviolet radiation has resulted in the need for a second level of p53-regulation. The results are important for furthering our understanding of how p53, the tumor suppressor, is regulated, and also offers intriguing hints about how these regulatory mechanisms might have evolved."

While speculations about how the mechanism evolv
'"/>

Contact: Sarah L. White, Ph.D.
swhite@licr.org
917-974-7952
Ludwig Institute for Cancer Research
10-Sep-2006


Page: 1 2

Related biology news :

1. Ethnicity plays a role in neonatal deaths
2. Protein chatter linked to cancer activation
3. Newly created cancer stem cells could aid breast cancer research
4. Green tea boosts production of detox enzymes, rendering cancerous chemicals harmless
5. ESF EURYI award winner aims to stop cancer cells reading their own DNA
6. No evidence that widely prescribed statins protect against prostate cancer
7. A study by the MUHC and McGill University opens a new door to understanding cancer
8. New study suggests Concord grape juice may provide protection against breast cancer
9. New test improves detection of liver cancer
10. High-intensity ultrasound may launch attack on cancer, wherever it lurks
11. Unknotting DNA clue to cancer syndrome

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/21/2020)... ... August 18, 2020 , ... Sentien ... announced that the U.S. Food and Drug Administration (FDA) has approved the company’s ... for the treatment of severe COVID-19. Approval of this IND allows Sentien to ...
(Date:8/12/2020)... ... August 11, 2020 , ... Both Roche, based ... entered into license agreements with Housey Pharma’s HMI subsidiary to gain access to ... have annual Research and Development spending in excess of US $10 billion. , ...
(Date:8/5/2020)... ... August 05, 2020 , ... Regenative Labs has received approval from ... and ProText™, making them the first Wharton’s jelly allografts to be assigned a Q ... company’s solutions are the first Wharton’s jelly allograft product to be recognized as a ...
Breaking Biology News(10 mins):
(Date:7/18/2020)... ... 2020 , ... After research model surgery and catheter implantation, the long journey ... the beginning of a successful study, while protecting and accessing the catheter or device ... of Surgery from Envigo in a live webinar on Wednesday, ...
(Date:7/18/2020)... ... July 16, 2020 , ... Medial EarlySign , a ... prevention of high-burden diseases, and Centric Consulting, a business and technology consulting firm, ... existing data in order to identify and prioritize patients for care. , Combining ...
(Date:7/10/2020)... ... 2020 , ... Bode Technology, a leading provider ... through its COVID-19 testing service, Bode-CARES . Bode-CARES combines high-volume clinical testing ... provides a turnkey solution that includes a comprehensive collection and virus-management program for ...
(Date:7/10/2020)... HONG KONG (PRWEB) , ... July 09, 2020 ... ... chemical compound called 1-phenyl-2-thiourea (PTU) is commonly used to suppress pigment formation in ... years, the PolyU research team led by Dr MA has been using the ...
Breaking Biology Technology:
Cached News: